Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs

Abstract Background Dogs with chronic enteropathies (CE) displayed elevated IgA seropositivity against specific markers that can be used to develop a novel test. Objective To assess a multivariate test to aid diagnosis of CE in dogs and to monitor treatment‐related responses. Animals One hundred fif...

Full description

Bibliographic Details
Main Authors: Juan Estruch, Jacqueline Johnson, Sarah Ford, Sean Yoshimoto, Tracy Mills, Philip Bergman
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Journal of Veterinary Internal Medicine
Subjects:
Online Access:https://doi.org/10.1111/jvim.16132
id doaj-86ccc436c8df4ca19c5ad1cc2bb5d837
record_format Article
spelling doaj-86ccc436c8df4ca19c5ad1cc2bb5d8372021-07-14T06:50:33ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762021-05-013531306131510.1111/jvim.16132Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogsJuan Estruch0Jacqueline Johnson1Sarah Ford2Sean Yoshimoto3Tracy Mills4Philip Bergman5Vetica Labs, Inc. San Diego California USACabrillo Pet Hospital San Diego California USADepartment of Internal Medicine Blue Pearl Specialty Scottsdale Arizona USADepartment of Internal Medicine West LA Animal Hospital Los Angeles California USADepartment of Clinical Studies West LA Animal Hospital Los Angeles California USADepartment of Internal Medicine Katonah Bedford Veterinary Center New York New York USAAbstract Background Dogs with chronic enteropathies (CE) displayed elevated IgA seropositivity against specific markers that can be used to develop a novel test. Objective To assess a multivariate test to aid diagnosis of CE in dogs and to monitor treatment‐related responses. Animals One hundred fifty‐seven dogs with CE/inflammatory bowel disease (IBD), 24 dogs non‐IBD gastrointestinal disorders, and 33 normal dogs. Methods Prospective, multicenter, clinical study that enrolled dogs with gastrointestinal disorders. Serum sample collected at enrollment and up to 3 months follow‐up measuring OmpC (ACA), canine calprotectin (ACNA), and gliadin‐derived peptides (AGA) by ELISA. Results Seropositivity was higher in CE/IBD than normal dogs (66% vs 9% for ACA; 55% vs 15% for ACNA; and 75% vs 6% for AGA; P < .001). When comparing CE/IBD with non‐IBD disease, ACA and ACNA displayed discriminating properties (66%, 55% vs 12.5%, 29% respectively) while AGA separated CE from normal cohorts (54% vs 6%). A 3‐marker algorithm at cutoff of ACA > 15, ACNA > 6, AGA > 60 differentiates CE/IBD and normal dogs with 90% sensitivity and 96% specificity; and CE/IBD and non‐IBD dogs with 80% sensitivity and 86% specificity. Titers decreased after treatment (47%‐99% in ACA, 13%‐88% in ACNA, and 30%‐85% in AGA), changes that were concurrent with clinical improvements. Conclusion and Clinical Importance An assay based on combined measurements of ACA, ACNA, and AGA is useful as a noninvasive diagnostic test to distinguish dogs with CE/IBD. The test also has the potential to monitor response to treatment.https://doi.org/10.1111/jvim.16132calprotectinCE/IBDGI monitoringgliadinsOmpC
collection DOAJ
language English
format Article
sources DOAJ
author Juan Estruch
Jacqueline Johnson
Sarah Ford
Sean Yoshimoto
Tracy Mills
Philip Bergman
spellingShingle Juan Estruch
Jacqueline Johnson
Sarah Ford
Sean Yoshimoto
Tracy Mills
Philip Bergman
Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs
Journal of Veterinary Internal Medicine
calprotectin
CE/IBD
GI monitoring
gliadins
OmpC
author_facet Juan Estruch
Jacqueline Johnson
Sarah Ford
Sean Yoshimoto
Tracy Mills
Philip Bergman
author_sort Juan Estruch
title Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs
title_short Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs
title_full Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs
title_fullStr Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs
title_full_unstemmed Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs
title_sort utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs
publisher Wiley
series Journal of Veterinary Internal Medicine
issn 0891-6640
1939-1676
publishDate 2021-05-01
description Abstract Background Dogs with chronic enteropathies (CE) displayed elevated IgA seropositivity against specific markers that can be used to develop a novel test. Objective To assess a multivariate test to aid diagnosis of CE in dogs and to monitor treatment‐related responses. Animals One hundred fifty‐seven dogs with CE/inflammatory bowel disease (IBD), 24 dogs non‐IBD gastrointestinal disorders, and 33 normal dogs. Methods Prospective, multicenter, clinical study that enrolled dogs with gastrointestinal disorders. Serum sample collected at enrollment and up to 3 months follow‐up measuring OmpC (ACA), canine calprotectin (ACNA), and gliadin‐derived peptides (AGA) by ELISA. Results Seropositivity was higher in CE/IBD than normal dogs (66% vs 9% for ACA; 55% vs 15% for ACNA; and 75% vs 6% for AGA; P < .001). When comparing CE/IBD with non‐IBD disease, ACA and ACNA displayed discriminating properties (66%, 55% vs 12.5%, 29% respectively) while AGA separated CE from normal cohorts (54% vs 6%). A 3‐marker algorithm at cutoff of ACA > 15, ACNA > 6, AGA > 60 differentiates CE/IBD and normal dogs with 90% sensitivity and 96% specificity; and CE/IBD and non‐IBD dogs with 80% sensitivity and 86% specificity. Titers decreased after treatment (47%‐99% in ACA, 13%‐88% in ACNA, and 30%‐85% in AGA), changes that were concurrent with clinical improvements. Conclusion and Clinical Importance An assay based on combined measurements of ACA, ACNA, and AGA is useful as a noninvasive diagnostic test to distinguish dogs with CE/IBD. The test also has the potential to monitor response to treatment.
topic calprotectin
CE/IBD
GI monitoring
gliadins
OmpC
url https://doi.org/10.1111/jvim.16132
work_keys_str_mv AT juanestruch utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs
AT jacquelinejohnson utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs
AT sarahford utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs
AT seanyoshimoto utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs
AT tracymills utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs
AT philipbergman utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs
_version_ 1721303942301745152